<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> (MetS) is defined as abdominal central <z:hpo ids='HP_0001513'>obesity</z:hpo>, atherogenic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The rapid increasing prevalence of MetS and the consequent diseases, such as type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disorder</z:e>, are becoming a global epidemic health problem </plain></SENT>
<SENT sid="2" pm="."><plain>Despite considerable research into the etiology of this complex disease, the precise mechanism underlying MetS and the association of this complex disease with the development of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and increased <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> remains elusive </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, researchers continue to actively search for new MetS treatments </plain></SENT>
<SENT sid="4" pm="."><plain>Recent animal studies have indicated that the galanin <z:chebi fb="7" ids="16670">peptide</z:chebi> family of <z:chebi fb="7" ids="16670">peptides</z:chebi> may increase food intake, <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo>, fat preference and the risk for <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> while decreasing <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and blood pressure, which diminishes the probability of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>To date, however, few papers have summarized the role of the galanin <z:chebi fb="7" ids="16670">peptide</z:chebi> family in modulating MetS </plain></SENT>
<SENT sid="6" pm="."><plain>Through a summary of available papers and our recent studies, this study reviews the updated evidences of the effect that the galanin <z:chebi fb="7" ids="16670">peptide</z:chebi> family has on the clustering of MetS components, including <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>This line of research will further deepen our understanding of the relationship between the galanin <z:chebi fb="7" ids="16670">peptide</z:chebi> family and the mechanisms underlying MetS, which will help develop new therapeutic strategies for this complex disease </plain></SENT>
</text></document>